InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.09
(
0.27%
)
US TECH 100
19,250.80
(
0.45%
)
Dow Jones
39,169.52
(
0.13%
)
Brent Oil
86.69
(
0.18%
)
Bitcoin
62,753.26
(
-0.15%
)
Post# of 252455
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119964
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 104041

Sunday, 10/31/2010 10:26:56 PM

Sunday, October 31, 2010 10:26:56 PM

Post# of 252455
VRTX reports that 58% and 65% of patients in the Telaprevir ADVANCE and ILLUMINATE studies, respectively, stopped treatment at 24 weeks according to the response-guided protocol in these studies:

http://finance.yahoo.com/news/New-Data-From-Phase-3-Studies-bw-2646849491.html?x=0&.v=1

(Unlike the ADVANCE and ILLUMINATE studies in the first-line setting, VRTX's REALIZE study in the second-line setting treated all patients for 48 weeks regardless of the response.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up